Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis (Rh-GIOP)
Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Frank Buttgereit, Prof Dr
- Phone Number: +49 30 450 513125
- Email: frank.buttgereit@charite.de
Study Contact Backup
- Name: Edgar Wiebe, Dr
- Phone Number: +49 30 450 513192
- Email: gerd.burmester@charite.de
Study Locations
-
-
-
Berlin, Germany, 10117
- Recruiting
- Charité University Medicine Berlin (CCM)
-
Contact:
- Frank Buttgereit, Prof Dr
- Phone Number: +49 30 450 513125
- Email: frank.buttgereit@charite.de
-
Contact:
- Gerd-Rüdiger Burmester, Prof Dr
- Phone Number: +49 30 450 513192
- Email: gerd.burmester@charite.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Every patient has to fulfill the following inclusion criteria:
- patients with (control group: without) a diagnosis of a chronic inflammatory rheumatic disease or psoriasis
- patients who (not for control groups) have/had already a glucocorticoid therapy, or patients in which the implementation of a new long-term GC therapy is expected
- patients who, according to the Dachverband Osteologie (DVO, Germany) guidelines, attend our osteoporosis and bone metabolism outpatient consultation hours or are referred by the hospital wards of the Charité for diagnosis, treatment or follow-up
- capability to understand the patient information
- consent to participation in the project and storage of data
Exclusion Criteria:
If any of the following exclusion criteria is true, the patient must not be included in this study:
- alcohol, medication and/or drug addiction
- severe psychiatric diseases limiting the comprehension of the project plan and the study protocol (persons incapable of giving informed consent)
- pregnant and lactating patients
- patients incapable of giving informed consent for any reason
- prisoners and all persons who are committed to an institution due to an official or judicial order
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Rh-GIOP(A)
Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
|
Glucocorticoid treatment
Other Names:
|
|
Rh-GIOP(B)
Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
|
Glucocorticoid treatment
Other Names:
|
|
Rh-GIOP(C)
Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone mineral density
Time Frame: 2 - 5 years
|
T-score (measured by DEXA; statistical evaluation on group levels, lower values are considered as being more dangerous)
|
2 - 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean daily glucocorticoid dosage
Time Frame: 1 day - 25 years
|
Mean daily dosage in milligram prednisone equivalent per day (measured by questionnaire; averaged values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)
|
1 day - 25 years
|
|
Cumulative glucocorticoid dosage
Time Frame: at least 1 day - 25 years
|
Cumulative glucocorticoid dosage in gram (measured by questionnaire; summed values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)
|
at least 1 day - 25 years
|
|
Duration of glucocorticoid dosage
Time Frame: from 1 day - 25 years
|
Duration of glucocorticoid therapy in days (measured by questionnaire; statistical evaluation on group levels; higher values are considered as being more dangerous)
|
from 1 day - 25 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Frank Buttgereit, Prof Dr, Charité University Medicine Berlin (CCM)
Publications and helpful links
General Publications
- Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit F. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis-2015-208916. Epub 2016 Mar 1.
- Buttgereit F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol. 2020 Apr;16(4):239-246. doi: 10.1038/s41584-020-0370-z. Epub 2020 Feb 19.
- Wiebe E, Huscher D, Schaumburg D, Palmowski A, Hermann S, Buttgereit T, Biesen R, Burmester GR, Palmowski Y, Boers M, Stone JH, Dejaco C, Buttgereit F. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. 2022 Aug 11;81(9):1313-1322. doi: 10.1136/annrheumdis-2022-222339.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Arthritis
- Joint Diseases
- Metabolic Diseases
- Connective Tissue Diseases
- Infections
- Skin Diseases, Papulosquamous
- Skin Diseases
- Bone Diseases, Metabolic
- Gram-Positive Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Osteoporosis
- Psoriasis
- Rheumatic Diseases
- Collagen Diseases
- Rheumatic Fever
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Neuroprotective Agents
- Methylprednisolone
- Glucocorticoids
Other Study ID Numbers
Other Study ID Numbers
- EA1/367/14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.